Lineage Cell Therapeutics vs Surrozen
LCTX and SRZN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LCTX and SRZN compare
Surrozen is the larger company, worth 1.6 times as much as Lineage Cell Therapeutics ($372M against $231M).
Lineage Cell Therapeutics grew revenue faster over the last twelve months (0.18% versus −8.8% for Surrozen).
Lineage Cell Therapeutics keeps more of each dollar of sales as profit, with a net margin of 16.2% compared with −2885% at Surrozen.
Lineage Cell Therapeutics scores higher on the StockData Score (8 against 5 for Surrozen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LCTX | SRZN |
|---|---|---|
| Size and price | ||
| Market cap | $231M | $372M |
| Share price | $0.915 | $31.61 |
| Change, 1 year | −52.6% | 144% |
| Change, 5 years | −60.1% | −77.1% |
| Beta (5Y) | 0.96 | 0.52 |
| Employees | 77 | 44 |
| StockData Score | ||
| Total score | 8 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 3 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 21.3× (better) | 32.3× |
| P/B | 3.4× | – |
| FCF yield | −11.4% | −9.4% (better) |
| Fair value | $0.620 | – |
| Margin of safety | −47.6% | – |
| Growth | ||
| Revenue growth (TTM) | 0.18% (better) | −8.8% |
| Revenue growth, 5Y average | 51.5% | – |
| Profitability | ||
| Operating margin | −280% (better) | −385% |
| Net margin | 16.2% (better) | −2885% |
| FCF margin | −244% (better) | −304% |
| Return on equity | 3.9% | – |
| Return on invested capital | −1395% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 5.96 | 12.14 (better) |
| Altman Z-score | −2.87 (better) | −6.78 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | – | −0.94% |
| Shareholder yield | 0.00% (better) | −0.94% |
| Ownership | ||
| Held by institutions | 46.1% | 91.3% |
| Held by insiders | 74.4% | 44.5% |
| Insider net buying, 12 months | $24.4K | $1.6M (better) |
| Short interest, % of float | 37.7% | 49.6% |
Go deeper
- LCTX stock overview
- LCTX income statement
- LCTX valuation and score
- SRZN stock overview
- SRZN income statement
- SRZN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.